BRM-01
BRM-01 is a reversible chemical modification of the L-Dopa molecule which increases the solubility in water and polar aprotic solvents significantly. The cleavage of the L-DOPA derivative leads to L-DOPA and a biocompatible molecule which goes into the normal human metabolism. Continuous application over several days with one pump filling is possible due to the low volume of BRM-01 solution required per day. As a result, management of pump and application materials especially by the advanced PD patient or his caretaker becomes much easier and has a lower potential of causing complications. Berlirem is, therefore, convinced that the innovative continuous infusion therapy with BRM-01 will set a new treatment paradigm in Parkinson’s disease.

BRM-02

BRM-02 is, close to BRM-01, a reversible chemical modification of the L-Dopa molecule which increases the solubility in water and polar aprotic solvents significantly. The cleavage of the L-DOPA derivative leads to L-DOPA and a biocompatible molecule which goes into the normal human metabolism. BRM-02 is stable in a wide pH range and can be formulated according to BRM-01.

BRM-03

BRM-03 is, close to BRM-01, a reversible chemical modification of the L-Dopa molecule which increases the solubility in water and polar aprotic solvents significantly. The cleavage of the L-DOPA derivative leads to L-DOPA and a biocompatible molecule which goes into the normal human metabolism. BRM-03 is stable in a wide pH range and can be formulated according to BRM-01.

BRM-04

BRM-04 is named as a range of potential substances which combines the L-DOPA molecule with several short-chained carbohydrates. This leads to an improved solubility of the compounds and an outstanding biocompatibility. BRM-04 is expected to be stable in a wide pH range and can be formulated according to BRM-01.